GlytiNa Duo Tablets 2.5/850mg
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samik Pharmaceutical Co., Ltd.
MFDS item code 201906452 · Approved 2019.09.16
This product's status changed to Expired on 2024.09.16. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of blood glucose control in adults with type 2 diabetes mellitus
This drug is used in conjunction with diet and exercise to help control blood glucose in adult patients with type 2 diabetes. It may be prescribed for those who have never used diabetes medications before or have difficulty controlling blood sugar with monotherapy. Additionally, this drug can be used when metformin alone is insufficiently effective. It can also be added to the combination of linagliptin and metformin when blood sugar is not adequately controlled with metformin along with sulfonylureas or insulin. This drug can also be used in cases where it is necessary to enhance blood glucose control in combination with empagliflozin. In short, this drug helps improve blood glucose control at various treatment stages.
The dose of this medicine should be determined for each patient based on the current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with Caution in the Following Patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in treatment for type 2 diabetes may result in a change in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate [eGFR] 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Patients in Whom This Medicine Must Not Be Administered).
This drug can cause serious metabolic complications known as lactic acidosis, and it should not be administered to patients with impaired kidney function or acute illnesses. It is not safe to use in patients with type 1 diabetes or in pregnant or breastfeeding women. When used in conjunction with sulfonylureas or insulin, there is a risk of hypoglycemia, so blood glucose changes should be monitored closely while taking this medication. Elderly patients or those with kidney disease should undergo regular kidney function tests and this drug should not be used if kidney function is severely impaired. In cases of acute myocardial infarction, shock, severe infections, or other situations where the body condition deteriorates rapidly, the intake of this medication should be temporarily suspended. Caution should also be exercised in patients with liver dysfunction and if symptoms of liver dysfunction develop, medical consultation should be sought immediately. Patients with alcohol abuse or acute alcohol intoxication are at increased risk of lactic acidosis if they take this medication and should avoid it. During treatment, acute pancreatitis or skin conditions such as bullous pemphigoid may occur, and in case of persistent severe abdominal pain or development of vesicles on the skin, immediate medical attention is required. Vitamin B12 levels may decrease, so regular monitoring for vitamin B12 deficiency is necessary with long-term use. This drug may interact with other medications, so if taking other medications, it's crucial to consult with a physician or pharmacist. Pregnant women or those who might become pregnant should avoid using this medication and consider alternative treatments for blood glucose control. It is not recommended for children under 10 years old, and safety and efficacy have not been fully established for children aged 10 to 17. Elderly patients are more prone to impaired kidney function, so it is important to start with the minimum dosage and regularly monitor kidney function. In case of overdose, there is a risk of lactic acidosis, and immediate medical treatment is necessary, which may include hemodialysis. This medication should be stored out of reach of children, kept away from moisture, and should not be transferred to different containers.
nasopharyngitis, hypersensitivity, angioedema, urticaria, lactic acidosis, vitamin B12 deficiency and decrease, hypoglycemia, taste disorder, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, blistering dermatitis, severe joint pain with disability, rhabdomyolysis, increased lipase, increased amylase, diarrhea, hypoglycemia, stomatitis, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech disorder, Alzheimer's dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage kidney disease, acute cholangitis, acute cholecystitis, cholangitis, hearing loss, dizziness, erectile dysfunction, goiter, kidney transplant failure, anemia, headache, sensory disturbance, postherpetic neuralgia, hemiparesis, syncope, drowsiness, chest discomfort, asthenia, epistaxis, oropharyngeal pain, voice disorder, nasal bleeding, hypertension, male pattern hair loss, hyperhidrosis, hair loss, dermatitis, anxiety, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, laceration, dry eye, glaucoma, cataract, eye discomfort, allergic conjunctivitis, polyuria, proteinuria, stress incontinence, hematuria, hypotension, flushing, hepatic steatosis, cholelithiasis, hearing loss, benign prostatic hyperplasia, confusion state, nocturia, pruritus, angina, palpitations, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, dyspepsia, rectal bleeding, cheilitis, caries, enteritis, gastritis, stomatitis, increased triglycerides in the blood, decreased hemoglobin, increased potassium in the blood, increased creatinine in the blood, increased creatine phosphokinase in the blood, increased ALT, increased AST, increased blood glucose, increased glycated hemoglobin, hypercholesterolemia, dyslipidemia, joint pain, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, unstable angina
Not everyone experiences these, and they can vary from person to person.
This drug may be sensitive to air and moisture, so it is important to store it in a sealed container. Additionally, the medication should be stored at room temperature, specifically between 1 to 30 degrees Celsius, to maintain its efficacy.
Bright orange, biconvex, oval-shaped film-coated tablet
60 tablets (10 tablets/PTPX6)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samik Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.